AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02166333 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: 2000 IU/d cholecalciferol
Study NCT02166333 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: 4000 IU/d cholecalciferol
Study NCT00447174 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Dyadic treatment for parental bereavement
Study NCT00352742 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ATN-224 + bortezomib
Description: ATN-224 and bortezomib dose to be determined in Phase I portion of study
Study NCT04455867 — intervention group
Intervention type: BEHAVIORAL
Intervention: Diabetes Exercise and Healthy Lifestyle Program
Description: The program combines exercise, education and healthy lifestyle behaviour changes. Participants will begin the program with a cardiopulmonary exercise assessment. Then the team will create a personalized program of exercise based on functional abilities and personal goals. Participants will attend 1 supervised exercise class a week, which includes a warm-up and stretching routine, aerobic exercise (walking, stationary cycling or elliptical machine), resistance training and an educational session. This program also offers peer-to-peer support and encourages participants to carry out their own exercise program at home 4 more times per week and to keep a weekly exercise diary to help them with their progress.
Study NCT04455867 — intervention group
Intervention type: OTHER
Intervention: Outpatient care
Description: Participants receive usual care from outpatient services, which may include Endocrinology, Family Medicine, or Diabetes Education
Study NCT00349219 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: erlotinib
Description: erlotinib 150 mg taken orally daily until disease progression
Study NCT01275521 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BONT-A intra-prostatic injection
Description: • Intra prostatic injection of 200 IU of BONT-A (2 x 100 IU to dilute in 10 cc salted serum), divided into 4 injections, 2 in each prostate lobe for a volume intra injected 2.5 cc per site.~Interruption of the medical therapy 1 month after the injection;
Study NCT01275521 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Optimized medical BPH treatment
Description: Optimization of the medical therapy according to recent guidelines
Study NCT00646607 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FOLFOX (Oxaliplatin, 5Fluorouracil, Lederfolin)
Description: To assess whether a 3-month FOLFOX-4 treatment is at least equivalent to a 6-month FOLFOX-4 treatment
Study NCT00646607 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: FOLFOX (Oxaliplatin, 5Fluorouracil, Lederfolin)
Description: standard treatment
Study NCT01135901 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioural change programme
Description: The programme consists of a introductory course, organised physical activity 2-3 times a week, meetings every 3rd month with lectures and theme nights, and organising self-help groups.
Study NCT01139801 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxytocin
Description: Foley balloon placement with intravenous low dose oxytocin administration starting 2 milliunits per minute.
Study NCT01139801 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Misoprostol
Description: Misoprostol, 25 mcg, is placed intravaginally into the posterior fornix of the vagina in conjunction with Foley balloon placement
Study NCT02676518 — intervention group
Intervention type: OTHER
Intervention: serum
Description: Serum for serum anti-Mullerian hormone, 2-hour 75 gram oral glucose tolerance test and lipid profiles
Study NCT02964910 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Recombinant Hepatitis E Vaccine (Escherichia Coli)
Description: Participants would receive 3 doses of Recombinant Hepatitis E Vaccine (Escherichia Coli) intramuscularly at 0, 1, 6 month.
Study NCT02964910 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Recombinant Hepatitis E Vaccine (Escherichia Coli)
Description: Participants would receive 3 doses of Recombinant Hepatitis E Vaccine (Escherichia Coli) intramuscularly at 0, 1, 6 month.
Study NCT01129518 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Glyco-conjugate Neisseria meningitidis serogroup C (MenC) vaccine
Description: In order to ensure proper intramuscular injection of the study vaccines, a 23G (0.5mm in diameter) needle of at least 1 inch (2.54 cm) length will be used. All vaccines will be administered intramuscularly.~Then MenC vaccine will administered either once (at 3 months) or twice (at 3 and 4 months) depending on treatment group to either the thigh, deltoid or a combination of the two.
Study NCT00349219 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cisplatin
Description: cisplatin 80 mg/m2 IV day 1 every 3 weeks given in second-line therapy
Study NCT01129518 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Routine schedule immunisations except monovalent MenC vaccine
Description: Routine schedule immunisations will be given according to NHS guidelines.
Study NCT00902278 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Flulaval
Description: one 0.5-mL dose via intramuscular injection
Study NCT00902278 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Fluvirin
Description: one 0.5-mL dose via intramuscular injection
Study NCT00902278 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Fluzone
Description: one 0.5-mL dose via intramuscular injection
Study NCT00902278 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Fluarix
Description: one 0.5-mL dose via intramuscular injection
Study NCT00902278 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Afluria
Description: one 0.5-mL dose via intramuscular injection
Study NCT01506986 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lansoprazole 30mg, Clarithromycin 500mg, Metronidazole 400mg
Description: All three medications will be taken orally, twice daily, for seven days.
Study NCT01506986 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo lansoprazole 30mg, clarithromycin 500mg, metronidazole 400mg
Description: Medication to be taken orally, twice a day, for seven days.
Study NCT01614158 — intervention group
Intervention type: DEVICE
Intervention: perimetry
Description: perimetric examination using static stimuli, assessing the entire (80 degree) visual field with a fast thresholding algorithm (GATE) \[Schiefer 2008\] to know the extent/ magnitude of the visual field defect and its variability within the cohort and over time
Study NCT01614158 — intervention group
Intervention type: OTHER
Intervention: D-BCVA
Description: D-BCVA using EDTRS chart
Study NCT01614158 — intervention group
Intervention type: OTHER
Intervention: RAPD
Description: RAPD using swinging flashlight test
Study NCT02011568 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Therapeutic Hypothermia
Study NCT02011568 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Therapeutic Hypothermia
Study NCT03362853 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nemonoxacin 500Mg Capsule
Description: Receive a single dose in a fasting state
Study NCT03362853 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nemonoxacin 500Mg Capsule
Description: Receive a single dose in a fasting state
Study NCT03362853 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Nemonoxacin 500Mg Capsule
Description: Receive a single dose in a fasting state
Study NCT03362853 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Moxifloxacin 400Mg Tablet
Description: Receive a single dose in a fasting state
Study NCT03362853 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Moxifloxacin 400Mg Tablet
Description: Receive a single dose in a fasting state
Study NCT03362853 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Moxifloxacin 400Mg Tablet
Description: Receive a single dose in a fasting state
Study NCT03362853 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nemonoxacin 750Mg Capsule
Description: Receive a single dose in a fasting state
Study NCT03362853 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nemonoxacin 750Mg Capsule
Description: Receive a single dose in a fasting state
Study NCT03362853 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Nemonoxacin 750Mg Capsule
Description: Receive a single dose in a fasting state
Study NCT03362853 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo oral capsule
Description: Receive a single dose in a fasting state
Study NCT03362853 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo oral capsule
Description: Receive a single dose in a fasting state
Study NCT00349219 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gemcitabine
Description: gemcitabine 1200 mg/m2 IV days 1 and 8 every 3 weeks, given in second-line
Study NCT00349219 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: cisplatin
Description: cisplatin 80 mg/m2 IV day 1 every 3 weeks for 6 cycles
Study NCT03362853 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral capsule
Description: Receive a single dose in a fasting state
Study NCT00037934 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Upper extremity robot
Description: Robotic upper extremity neuro-rehabilitation
Study NCT01614158 — intervention group
Intervention type: DEVICE
Intervention: IOP
Description: IOP using applanation tonometer
Study NCT01614158 — intervention group
Intervention type: DEVICE
Intervention: Spectralis OCT
Description: RNFT and RNFV using Spectralis OCT (star scan, ring scan 2,8 mm and volume scan)
Study NCT01614158 — intervention group
Intervention type: OTHER
Intervention: Fundus photography
Description: Optic disk morphology will be documented by fundus photography
Study NCT04419701 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: periarticular infiltration
Description: The cocktail will be injected at the following 7 anatomical zones as follows:~Zone 1: medial retinaculum Zone 2: medial collateral ligament and medial meniscus capsular attachment Zone 3: posterior capsule Zone 4: lateral collateral ligament and lateral meniscus capsular attachment Zone 5: lateral retinaculum Zone 6: patellar tendon and fat pad Zone 7: cut ends of quadriceps muscle and tendon Injection at zones 2, 3, and 4 will be administered after making the tibial and femoral cuts and ligament balancing. At zones 1, 5, 6, and 7, the injection will be administered after implant placement.
Study NCT04419701 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: genicular nerve block
Description: The genicular arteries will be identified near the periosteal areas, which are the junctions of the epicondyle and the shafts of the femur and tibia, and confirmed by color Doppler ultrasound. genicular nerve block target points should be next to each genicular artery because the superior lateral, superior medial, and inferior medial genicular artery traveled along each genicular nerve.After using color Doppler to confirm the genicular artery, the needle will be inserted in the plane of the ultrasound probe in the long-axis view.
Study NCT01389700 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SAR279356
Description: Pharmaceutical form: solution for infusion~Route of administration: intravenous infusion
Study NCT01389700 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Pharmaceutical form: solution for infusion~Route of administration: intravenous infusion
Study NCT02539979 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paracetamol
Study NCT02539979 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo - Normal Saline
Description: Normal Saline 100cc
Study NCT03837340 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CMHT
Description: Community mental health teams (CMHTs) delivering evidence-based interventions to people with SMI, inspired by the Flexible Assertive Community Treatment (FACT) service delivery model.
Study NCT03837340 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: CAU
Description: Care as usual (CAU) usually consisting of inpatient psychiatric care or outpatient care prescribing medication.
Study NCT00915980 — intervention group
Intervention type: PROCEDURE
Intervention: gastric bypass surgery and testing
Description: The patients will be tested with OGTT and meal testing before and after undergoing gastric bypass surgery.
Study NCT02394379 — intervention group
Intervention type: DEVICE
Intervention: Trulign™ Toric IOL
Description: Trulign™ Toric Posterior Chamber IOL is a modified plate haptic lens
Study NCT00016406 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: filgrastim
Study NCT00016406 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: cyclophosphamide
Study NCT00016406 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide
Study NCT00016406 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: doxorubicin
Study NCT00016406 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: doxorubicin
Study NCT00016406 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: paclitaxel
Study NCT00016406 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paclitaxel
Study NCT00016406 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: surgery
Study NCT00016406 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: surgery
Study NCT00003892 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ISIS 5132
Description: 4mg/kg/day IV for 21 days every 4 weeks.
Study NCT03790020 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine
Description: In our study this local anesthetic agent will be applied for postoperative pain relief
Study NCT04222478 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Specific auriculotherapy
Description: 3 sessions of auriculotherapy with semi-permanent needles on the 6 points according to the protocol of Alimi at one month intervals.
Study NCT04222478 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Non-specific auriculotherapy
Description: 3 sessions of auriculotherapy with semi-permanent needles on non-specific points.
Study NCT03147040 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Chemotherapy treatment with carboplatin and atezolizumab
Study NCT03147040 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Chemotherapy treatment with carboplatin and atezolizumab
Study NCT01021696 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paracetamol
Description: Paracetamol Max. dose: 3g/d
Study NCT01021696 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Morphine
Description: Morphine ret. Tab. 5mgx2/d; max. dose:10mgx2/d
Study NCT01021696 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Buprenorphine plaster
Description: 5ųg/h, change each 7.day; max. dose: 10ųg/h
Study NCT01021696 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pregabalin
Description: 25mgx1/d; max 300mg/d
Study NCT00157573 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GM-CSF, sargramostim
Description: GM-CSF subcutaneous injection
Study NCT03976817 — intervention group
Intervention type: PROCEDURE
Intervention: aortic valve replacement
Description: After median sternotomy, cardiopulmonary bypass (CPB) was established between the ascending aorta and the right atrium. The aorta was cross-clamped and a high potassium warm cardioplegia was infused and repeated every 15 minutes. The aortotomy was made above the sinuses and the aortic valve was removed. The prosthesis was chosen one size larger than the maximal sizer that could be inserted, which was also used to determine the appropriate height for insertion of the sutures along the wall of the non-coronary sinus.
Study NCT04311359 — intervention group
Intervention type: DRUG
Intervention: Drugs, Generic
Description: All drugs having 19 or more Brain Oedema cases reported to the FAERS database
Study NCT02619370 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Conversation card game
Study NCT02619370 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Active Control
Study NCT03606109 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tranexamic Acid (TXA)
Description: One gram of intravenous tranexamic acid (TXA) will be administrated before tourniquet inflation and before closure of the incision, as 1 g has been shown to be a safe amount with minimal side effects
Study NCT02752048 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 1 group: Placebo group. Oral administration for 24 weeks, BID after meal
Study NCT03888898 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Reusable respirator fit test and competency evaluation
Description: Feasibility of rapid conversion to reusable elastomeric respirator use during public health emergency
Study NCT03888898 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control fit test evaluation
Description: control comparator for fit testing time threshold
Study NCT03112317 — intervention group
Intervention type: OTHER
Intervention: Prevention of hypothermia
Description: Patients are routinely warmed with forced air warming blankets, regular blankets, pre warmed intravenous fluid. Routines are ensured with use of the WHO Surgical Safety Checklist. The intervention is the use of operating theatre care measures to prevent mild hypothermia in surgical patients.
Study NCT02430077 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Obeticholic Acid
Description: Capsules of obeticholic acid (OCA) or an identical placebo in the dose of 25 mg/day for a period of 4 months .
Study NCT02430077 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Identical to Obeticholic Acid - placebo drug
Study NCT05053282 — intervention group
Intervention type: OTHER
Intervention: endurance running exercise
Description: regular competitive or non-competitive running of medium and/or high intensity with the duration at least 20 minutes per session
Study NCT00274716 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK0736
Study NCT00274716 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK0916
Study NCT00274716 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Study NCT00274716 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT02863354 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aflibercept
Description: Intravitreal injection
Study NCT02291627 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MAC
Description: direct laryngoscopy
Study NCT02291627 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Coopdech
Description: Video laryngoscopy
Study NCT02291627 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AirTraq
Description: optical laryngoscopy
Study NCT00132769 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-0873
Description: MK-0873 1.25 mg twice daily for 12 weeks
Study NCT00132769 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Comparator: Placebo
Description: Matching placebo to MK-0873 1.25 mg twice daily for 12 weeks
Study NCT01866189 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PET and MRI
Description: F-MISO PET followed by brain MRI (MRI-1)(diffusion, FLAIR, perfusion, TOF)
Study NCT03832192 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: care.coach Avatar (HELP-Protocolized)
Description: care.coach human-in-the-loop avatar system with software-directed protocols based on the Hospital Elder Life Program (HELP).
Study NCT04955808 — intervention group
Intervention type: PROCEDURE
Intervention: Biospecimen Collection
Description: Undergo collection of tissue and blood samples
Study NCT04955808 — intervention group
Intervention type: OTHER
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT02420860 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Elotuzumab
Description: Given IV
Study NCT02420860 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: Given PO
Study NCT02420860 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT04693663 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Relex-Smile surgery
Description: surgery using Relex-Smile
Study NCT03099382 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: camrelizumab
Description: Subjects receive camrelizumab intravenous infusion at the dose 200mg on Day 1 every 2 weeks
Study NCT03099382 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Docetaxel
Description: Subjects receive Docetaxel intravenous infusion at the dose 75mg/m2 on Day 1 every 3 weeks
Study NCT00037934 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Upper extremity robot
Description: Robotic upper extremity neuro-rehabilitation
Study NCT00037934 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Traditional Supervised Upper Extremity Exercises
Description: Arm ergometer, reaching, and stretching exercises
Study NCT01918852 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Capecitabine